ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2344

Amelioration of Collagen-Induced Arthritis By Water-Soluble Fullerene C60(OH)36 Nanoparticles through the Inhibition of Angiogenesis

Chia-Tse Weng1,2, Shih-Yao Chen3, Yu-Hung Chen4, Chao-Liang Wu3, Ming-Fei Liu1,2, Ai-Li Shiau5 and Chrong-Reen Wang1,2, 1Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, 2Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, 3Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, 4Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, 5Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, Animal models, nanomedicine and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

Our previous study has shown that injection of 13-nm gold nanoparticles ameliorates collagen-induced arthritis (CIA) through the inhibition of angiogenesis by binding to VEGF. Fullerene derivatives, strong scavengers of superoxide radicals, have been recently identified as potential therapeutic agents for arthritis, with the ability to inhibit proinflammatory mediators. In this study, we demonstrate amelioration of CIA by treatment with C60(OH)36nanoparticles through the suppression of proinflammatory cytokine production, bone/cartilage erosion and synovial angiogenesis.

Methods

Physical properties of newly synthesized C60(OH)36 nanoparticles were characterized by X-ray photoelectron spectrometer, infra-red spectroscopy, fast-atom bombardment and matrix-assisted laser desorption/ionization mass spectroscopy, transmission electron microscope and dynamic light scattering analysis. Their ability to remove superoxide radicals was confirmed by the electron paramagnetic resonance spectrometer and the inhibition of intracellular reactive oxygen species formation in RAW 264.7 cells. Eight-week-old male Sprague-Dawley rats were immunized with bovine type II collagen emulsified in complete Freund’s adjuvant on day 0 and 7. Articular index was used to evaluate the therapeutic effect of the nanoparticles on arthritic joints receiving intra-articular injection of 10 mg nanoparticles or PBS as control (16 joints per group) on day 7. Histological and radiographic scores of arthritic joints were calculated upon sacrifice on day 21. Proinflammatory cytokines (IL-1b and TNF-a) and VEGF concentrations in homogenized synovium extracts were measured by enzyme-linked immunosorbent assay. Synovial angiogenesis was examined by counting microvessel numbers after immunohistochemical staining. The ability of nanoparticles to suppress endothelial cell proliferation was tested by using VEGF-treated human dermal microvascular endothelial cells-1 (HMVEC-1).

Results

Articular indexes of nanoparticles-injected joints were reduced as compared with PBS-treated counterparts. There were lower histological and radiographic scores with less pannus formation and erosion of cartilage/bone in nanoparticles-treated synovium. Reduced IL-1b concentrations were identified in the treatment group. Notably, nanoparticles-treated synovium had decreased microvessel density without reduction of VEGF levels, and nanoparticle treatment inhibited VEGF-induced HMVEC-1 proliferation in a dose-dependent manner, suggesting that the mechanism of angiogenesis inhibition was through the interference in the signal transduction pathway rather than physical adsorption of the growth factor.

Conclusion

This study demonstrates first that intra-articular injection of C60(OH)36 nanoparticles ameliorates CIA through anti-angiogenesis effect, further implicating a novel mechanism in application of certain fullerene derivatives as potential therapeutic agents in rheumatoid joints.


Disclosure:

C. T. Weng,
None;

S. Y. Chen,
None;

Y. H. Chen,
None;

C. L. Wu,
None;

M. F. Liu,
None;

A. L. Shiau,
None;

C. R. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/amelioration-of-collagen-induced-arthritis-by-water-soluble-fullerene-c60oh36-nanoparticles-through-the-inhibition-of-angiogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology